Target Name: UBE2V2P1
NCBI ID: G100128493
Review Report on UBE2V2P1 Target / Biomarker Content of Review Report on UBE2V2P1 Target / Biomarker
Other Name(s): ubiquitin conjugating enzyme E2 V2 pseudogene 1 | Ubiquitin-conjugating enzyme E2 variant 2 pseudogene 1

Introduction to UBE2V2P1, A Potential Drug Target

Drug targets and biomarkers play a critical role in the development of effective therapies and accurate diagnostic tools in the field of medicine. One such target that has gained significant attention in recent years is UBE2V2P1. This article aims to explore the significance of UBE2V2P1 as a potential drug target or biomarker in various diseases and its implications in personalized medicine.

What is UBE2V2P1?

UBE2V2P1, also known as Ubiquitin-conjugating enzyme E2 variant 2 pseudogene 1, is an RNA molecule that belongs to the pseudogene family. Pseudogenes were previously considered to be non-functional remnants of once-active genes, but recent studies have revealed their involvement in various biological processes. UBE2V2P1 is a transcript of a pseudogene located on chromosome 22q13.2.

Role of UBE2V2P1 as a Drug Target

1. Cancer: UBE2V2P1 has emerged as a potential drug target in the field of oncology. Studies have shown that its overexpression contributes to the growth and survival of cancer cells. Targeting UBE2V2P1 using small molecules or gene-targeting strategies can inhibit tumor growth and sensitize cancer cells to existing therapies. Furthermore, UBE2V2P1 inhibition has shown promising results in reducing metastasis, one of the major causes of cancer-related deaths.

2. Neurological Disorders: Neurodegenerative disorders like Alzheimer's and Parkinson's disease are characterized by the accumulation of toxic proteins. UBE2V2P1 has been implicated in the clearance of misfolded and aggregated proteins through the ubiquitin-proteasome system. Dysfunction of this system contributes to the pathogenesis of neurodegenerative diseases. Targeting UBE2V2P1 could potentially enhance the clearance of toxic protein aggregates and slow down disease progression.

3. Infectious Diseases: Recent studies have linked UBE2V2P1 to various infectious diseases. For instance, it has been identified as a host factor required for viral replication in several viral infections. Inhibition of UBE2V2P1 disrupts the viral life cycle and hinders viral replication, making it an attractive target for the development of antiviral therapies. Additionally, UBE2V2P1 has been shown to play a role in the immune response against certain bacterial infections, highlighting its potential as a target for immune-modulating therapies.

UBE2V2P1 as a Biomarker

1. Cancer Diagnosis and Prognosis: UBE2V2P1 has shown potential as a biomarker for cancer diagnosis and prognosis. Its overexpression has been observed in various cancer types, including colorectal, breast, and lung cancers. Elevated levels of UBE2V2P1 in patient samples can serve as an indicator of disease presence and aggressiveness. Additionally, monitoring changes in UBE2V2P1 expression during treatment can help assess treatment response and disease progression.

2. Response to Therapy: The expression of UBE2V2P1 has been associated with the response to certain therapies. In several studies, low levels of UBE2V2P1 have been linked to better response rates to chemotherapy or targeted therapies. Assessing UBE2V2P1 expression before initiating treatment could aid in predicting patient response and guiding personalized treatment decisions.

3. Disease Monitoring: UBE2V2P1 can also serve as a biomarker for disease monitoring. In neurodegenerative diseases, UBE2V2P1 levels could reflect the clearance capacity of misfolded proteins and provide insights into disease progression. Similarly, monitoring changes in UBE2V2P1 expression during viral infections could help evaluate the effectiveness of antiviral therapies and guide treatment adjustments.

Challenges and Future Directions

While the potential of UBE2V2P1 as a drug target or biomarker is promising, several challenges need to be addressed. Further research is required to unravel the functional mechanisms of UBE2V2P1 and its contribution to disease pathogenesis. Additionally, the development of specific inhibitors or diagnostic assays targeting UBE2V2P1 is necessary for its clinical translation.

In conclusion, UBE2V2P1 represents a promising drug target and biomarker in various diseases. Its involvement in cancer progression, neurodegenerative disorders, and infectious diseases highlights its therapeutic potential. As personalized medicine continues to gain momentum, the identification and utilization of biomarkers like UBE2V2P1 will play an essential role in tailoring treatments to individual patients, leading to improved outcomes in healthcare.

Protein Name: Ubiquitin Conjugating Enzyme E2 V2 Pseudogene 1

The "UBE2V2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2V2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

UBE2W | UBE2Z | UBE3A | UBE3B | UBE3C | UBE3D | UBE4A | UBE4B | UBFD1 | UBIAD1 | Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 | Ubiquitin E3 ligase (ASB2, TCEB1, TCEB2, CUL5, RNF7) complex | UBL3 | UBL4A | UBL4B | UBL5 | UBL5P3 | UBL7 | UBL7-DT | UBLCP1 | UBN1 | UBN2 | UBOX5 | UBOX5-AS1 | UBP1 | UBQLN1 | UBQLN1-AS1 | UBQLN2 | UBQLN3 | UBQLN4 | UBQLNL | UBR1 | UBR2 | UBR3 | UBR4 | UBR5 | UBR5-DT | UBR7 | UBTD1 | UBTD2 | UBTF | UBTFL1 | UBTFL2 | UBTFL6 | UBXN1 | UBXN10 | UBXN11 | UBXN2A | UBXN2B | UBXN4 | UBXN6 | UBXN7 | UBXN8 | UCA1 | UCHL1 | UCHL1-DT | UCHL3 | UCHL5 | UCK1 | UCK2 | UCKL1 | UCKL1-AS1 | UCMA | UCN | UCN2 | UCN3 | UCP1 | UCP2 | UCP3 | UDP-Glycosyltransferase | UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) | UEVLD | UFC1 | UFD1 | UFD1-AS1 | UFL1 | UFM1 | UFSP1 | UFSP2 | UGCG | UGDH | UGDH-AS1 | UGGT1 | UGGT2 | UGP2 | UGT1A1 | UGT1A10 | UGT1A3 | UGT1A4 | UGT1A5 | UGT1A6 | UGT1A7 | UGT1A8 | UGT1A9 | UGT2A1 | UGT2A2 | UGT2A3 | UGT2B10 | UGT2B11 | UGT2B15